
Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
Keywords: داروهای کاهش کلسترول; Alirocumab; Type 2 diabetes mellitus; Cardiovascular risk; Cholesterol-lowering drugs; Low-density lipoprotein cholesterol; Proprotein convertase subtilisin/kexin type 9;